Fortis Healthcare Limited has informed the Exchange about Investor Presentation
FORTIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fortis Healthcare reported strong Q1 FY26 results with consolidated revenue up 16.6% YoY at INR 2,167 Cr. Operating EBITDA jumped 43.2% to INR 491 Cr, with margin expanding sharply to 22.6% from 18.4% in Q1 FY25. Hospital business revenue grew 18.6% to INR 1,838 Cr with EBITDA margin at 22.1% (vs 18.5%), driven by 10.2% ARPOB growth and occupancy improvement to 69%. Diagnostics (Agilus) revenue grew 7.4% to INR 368.8 Cr with margin expanding to 23.0% from 16.1%. The company signed an O&M agreement with Gleneagles India to manage ~700 beds across 5 hospitals and completed acquisition of Shrimann Superspecialty Hospital in Jalandhar (228 beds). Net debt rose to INR 1,869 Cr (Net Debt/EBITDA at 0.92x vs 0.22x) due to acquisitions of Agilus stake and Fortis brand.
Strong quarter with broad-based margin expansion across hospital and diagnostics segments signals improved operational efficiency, likely to be viewed positively by investors. However, rising leverage from acquisitions (Net Debt/EBITDA up from 0.22x to 0.92x) is a watchpoint despite remaining comfortable. Strategic footprint expansion via Gleneagles O&M deal supports future revenue growth.